Kemudin I.M.

Active Ingredient:: Ceftriaxone
Origin:: EU

Kemudin I.M. (Ceftriaxone)

Q: What is Kemudin I.M. used for?

Kemudin I.M. contains ceftriaxone, a third‑generation cephalosporin indicated for serious bacterial infections such as community‑acquired pneumonia, bacterial meningitis, gonorrhea, urinary tract infections, skin and soft‑tissue infections, and intra‑abdominal infections.

Q: How does ceftriaxone work?

Ceftriaxone inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, blocking the final cross‑linking step of peptidoglycan formation. This weakens the wall, causing osmotic lysis and bacterial death, providing broad activity against many Gram‑negative and some Gram‑positive organisms.

Q: What determines the dose of Kemudin I.M.?

The dose of Kemudin I.M. is individualized by the prescribing clinician based on the infection type, severity, patient age, weight, renal and hepatic function, and local susceptibility patterns. No fixed regimen is provided here.

Q: Is Kemudin I.M. safe in pregnancy or breastfeeding?

Safety data for ceftriaxone in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and clinicians should assess each case carefully.

Q: How do I order Kemudin I.M. from GNH India?

To order Kemudin I.M., submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and import documentation.

Q: How does Kemudin I.M. compare with other antibiotics?

Kemudin I.M. (ceftriaxone) offers once‑daily dosing and high tissue penetration, distinguishing it from many penicillins and earlier‑generation cephalosporins that may require multiple daily doses. Compared with other third‑generation agents, ceftriaxone has a longer half‑life and broader Gram‑negative coverage, but resistance patterns should guide selection.

Q: How should Kemudin I.M. be stored and handled?

Kemudin I.M. should be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze or shake the vial. Before use, inspect for particulate matter and ensure the solution is clear.

Q: How is Kemudin I.M. administered?

Kemudin I.M. is given by intramuscular injection. The injection site should be selected according to standard clinical practice, and the volume administered should not exceed the recommended maximum for a single intramuscular dose to avoid local irritation.

Q: What are the most serious risks associated with Kemudin I.M.?

Serious risks include anaphylactic reactions, Clostridioides difficile‑associated colitis, hemolytic anemia, Stevens‑Johnson syndrome, and biliary sludge or pseudolithiasis. Prompt recognition and medical intervention are essential if any of these events occur.

Q: Who should not use Kemudin I.M.?

Kemudin I.M. is contraindicated in patients with a known hypersensitivity to ceftriaxone, other cephalosporins, or any component of the formulation. Caution is also advised in neonates younger than 28 days when given intramuscularly due to the risk of calcium precipitation.

Ceftriaxone, the active ingredient in Kemudin I.M., is a third‑generation cephalosporin presented as an injection for intramuscular use. It treats a range of serious bacterial infections in adults and children, including community‑acquired pneumonia, meningitis, gonorrhea, urinary tract infections, skin and soft‑tissue infections, and intra‑abdominal infections.

GNH India supplies Kemudin I.M. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Laboratórios Basi – Indústria Farmacêutica, S.A.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ceftriaxone is a broad‑spectrum third‑generation cephalosporin used to treat infections caused by susceptible bacteria.

Community‑acquired pneumonia: provides rapid bacterial eradication and clinical improvement.
Meningitis: achieves high cerebrospinal fluid concentrations to treat bacterial meningitis.
Gonorrhea: eliminates Neisseria gonorrhoeae, preventing complications.
Urinary tract infections: resolves infection caused by Gram‑negative organisms.
Skin and soft tissue infections: clears cellulitis and wound infections.
Intra‑abdominal infections: treats polymicrobial infections within the abdominal cavity.

How It Works

Ceftriaxone binds to penicillin‑binding proteins on the bacterial cell wall, inhibiting the final transpeptidation step of peptidoglycan synthesis. This disruption weakens the cell wall, leading to osmotic lysis and bacterial death. Its high affinity for a broad range of PBPs underlies activity against many Gram‑negative and some Gram‑positive organisms.

Side Effects

Ceftriaxone may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

Injection site pain: mild discomfort or tenderness at the intramuscular site.
Diarrhea: loose stools, often self‑limiting.
Nausea: occasional feeling of queasiness.
Rash: mild skin erythema or urticaria.
Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects

Anaphylaxis: severe allergic reaction with respiratory distress and hypotension.
Clostridioides difficile colitis: severe diarrhea due to intestinal flora disruption.
Hemolytic anemia: immune‑mediated destruction of red blood cells.
Stevens‑Johnson syndrome: severe mucocutaneous reaction.
Biliary sludge or pseudolithiasis: precipitation in gallbladder leading to abdominal pain.

Precautions & Warnings

When prescribing ceftriaxone, clinicians should consider several safety and handling precautions.

Renal impairment: adjust therapy and monitor renal function in patients with reduced kidney function.
Hepatic dysfunction: use cautiously and monitor liver enzymes in patients with liver disease.
Neonates and infants: avoid intramuscular use in neonates < 28 days due to risk of calcium precipitation.
Concomitant calcium‑containing solutions: do not mix with calcium salts to prevent precipitation.
Allergic history: assess for prior cephalosporin or penicillin hypersensitivity before administration.
Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Ceftriaxone can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid)

Calcium‑containing IV solutions: risk of insoluble calcium‑ceftriaxone precipitate.
Warfarin: may enhance anticoagulant effect, increasing bleeding risk.

Moderate Interactions (Monitor Closely)

Aminoglycosides: concurrent use may increase nephrotoxicity.
Loop diuretics: may potentiate electrolyte disturbances.
Oral contraceptives: may reduce effectiveness, advise additional contraceptive measures.
Antacids containing aluminum or magnesium: may affect absorption if given orally, though ceftriaxone is administered by injection.

Frequently Asked Questions

Kemudin I.M. contains ceftriaxone, a third‑generation cephalosporin indicated for serious bacterial infections such as community‑acquired pneumonia, bacterial meningitis, gonorrhea, urinary tract infections, skin and soft‑tissue infections, and intra‑abdominal infections.

Ceftriaxone inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, blocking the final cross‑linking step of peptidoglycan formation. This weakens the wall, causing osmotic lysis and bacterial death, providing broad activity against many Gram‑negative and some Gram‑positive organisms.

The dose of Kemudin I.M. is individualized by the prescribing clinician based on the infection type, severity, patient age, weight, renal and hepatic function, and local susceptibility patterns. No fixed regimen is provided here.

Safety data for ceftriaxone in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and clinicians should assess each case carefully.

To order Kemudin I.M., submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and import documentation.

Kemudin I.M. (ceftriaxone) offers once‑daily dosing and high tissue penetration, distinguishing it from many penicillins and earlier‑generation cephalosporins that may require multiple daily doses. Compared with other third‑generation agents, ceftriaxone has a longer half‑life and broader Gram‑negative coverage, but resistance patterns should guide selection.

Kemudin I.M. should be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze or shake the vial. Before use, inspect for particulate matter and ensure the solution is clear.

Kemudin I.M. is given by intramuscular injection. The injection site should be selected according to standard clinical practice, and the volume administered should not exceed the recommended maximum for a single intramuscular dose to avoid local irritation.

Serious risks include anaphylactic reactions, Clostridioides difficile‑associated colitis, hemolytic anemia, Stevens‑Johnson syndrome, and biliary sludge or pseudolithiasis. Prompt recognition and medical intervention are essential if any of these events occur.

Kemudin I.M. is contraindicated in patients with a known hypersensitivity to ceftriaxone, other cephalosporins, or any component of the formulation. Caution is also advised in neonates younger than 28 days when given intramuscularly due to the risk of calcium precipitation.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 17 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.